Glaxosmithkline’s Volibris Receives Authorisation From The European Commission For The Treatment Of Functional Class II And III PAH
April 29th, 2008 by 
admin GlaxoSmithKline (GSK) declared that the dweller Commission has issued marketing management for Volibris® (ambrisentan) for the communication of Pulmonary Arterial Hypertension (PAH) in patients categorised as World Health Organisation (WHO) Functional Class II and III, to meliorate training capacity. [i] Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related with connective paper disease.
Posted in Cardiology | 